Nasdaq

Bio-Path Holdings Reports Promising Preclinical Results for BP1001-A as a Potential Obesity Treatment in Type 2 Diabetes

Bio-Path Holdings, Inc. has announced promising preclinical results for its drug candidate BP1001-A, which targets obesity and related metabolic diseases in Type 2 diabetes patients. Recent studies ...
Nasdaq

Bio-Path Holdings Reports Milestone Achievement in Preclinical Studies for Obesity Treatment BP1001-A

Bio-Path Holdings, Inc. has announced significant progress with its drug BP1001-A, which has shown potential as a treatment for obesity and Type 2 diabetes in recent preclinical studies. The research ...
Seeking Alpha

Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity

HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (BPTH),, a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a ...
Business Insider

Bio-Path Holdings Highlights Advancements in Preclinical Discovery EffortsSelects New Drug Compound, BP1003, for Treatment of Pancreatic Cancer

HOUSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a ...